Heghine Khachatryan: Linking Coagulation, Inflammation, and Neurodegeneration In Neuro-Hemostasis Axis
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on Linkedin:
“The Neuro-Hemostasis Axis: Linking Coagulation, Inflammation, and Neurodegeneration
Emerging evidence is redefining our understanding of neurological disease, highlighting a critical and previously underappreciated interface between hemostasis and brain pathology.
The concept of the ‘neuro-hemostasis axis’ reflects a complex, bidirectional interplay between coagulation pathways, vascular biology, and neuroinflammatory mechanisms — positioning the hemostatic system as an active contributor to neurodegeneration, rather than a passive bystander.
Why This Matters
Accumulating data from translational and clinical studies demonstrate that key components of the hemostatic system exert direct effects on neural tissue:
- Thrombin — beyond coagulation, acts as a potent mediator of neuroinflammation, endothelial activation, and blood–brain barrier disruption
- Fibrin(ogen) — deposition within the central nervous system promotes microglial activation and neurotoxic signaling, accelerating neurodegenerative processes
- Platelets — actively participate in the amyloid cascade, contributing to vascular and neurodegenerative pathology
- Blood–brain barrier dysfunction — facilitates the entry of circulating coagulation factors into the CNS, amplifying inflammation and neuronal injury
A Paradigm Shift
This evolving framework challenges the traditional separation between vascular and neurodegenerative disorders.
Instead, it supports a unifying model in which:
Coagulation, inflammation, and neurodegeneration are mechanistically intertwined
This has profound implications for conditions such as:
- Alzheimer’s disease
- Vascular cognitive impairment
- Neuroinflammatory and paraneoplastic syndromes
Clinical and Research Implications
Understanding the neuro-hemostasis axis opens new avenues for:
- Early identification of at-risk patients
- Biomarker-driven stratification (e.g., fibrinogen, D-dimer, thrombin activity)
- Targeted therapeutic strategies modulating coagulation and inflammation
Take-Home Message
The brain is not isolated from the hemostatic system
it is deeply influenced by it.
Recognizing this connection is essential for advancing both diagnostic precision and therapeutic innovation in neurology and hematology.”
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Jul 8, 2026, 21:30Matthew Gouveia: How VNS-REHAB Is Transforming the Future of Stroke Rehabilitation
-
Jul 8, 2026, 21:22What Hundreds of Stroke Stories Have Taught Diana Kerr About Recovery and Resilience – Stroke Foundation
-
Jul 8, 2026, 19:50Heghine Khachatryan: Why the EHC Fully Supports the Lancet Commission on Women’s Hematological Health
-
Jul 8, 2026, 19:40Autoregulation Failure in SVD and Cognitive Impairment – International Journal of Stroke
-
Jul 8, 2026, 19:30Ahmed Mostafa: Why Antibodies Cause Organ Rejection
-
Jul 8, 2026, 19:28Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
-
Jul 8, 2026, 19:27Ahmadou Ouedraogo: Do You Know Your Blood Type?
-
Jul 8, 2026, 19:26Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
-
Jul 8, 2026, 19:25Paul Breillat: Nature Reviews Rheumatology Highlights Our VEXAS Syndrome Research